Fused ring heterocycle kinase modulators

Details Fused ring heterocycle kinase modulators Fused ring heterocycle kinase modulators

2008-09-22

2010-11-09

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S303000, C514S253040

Reexamination Certificate

active

07829558

ABSTRACT:
The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

REFERENCES:
patent: 5019586 (1991-05-01), Oxford et al.
patent: 5051412 (1991-09-01), Macor
patent: 5338849 (1994-08-01), Festal et al.
patent: 5563150 (1996-10-01), Curtis et al.
patent: 5643734 (1997-07-01), Henderson
patent: 5681959 (1997-10-01), Bishop et al.
patent: 6335342 (2002-01-01), Longo et al.
patent: 6589950 (2003-07-01), Collingwood et al.
patent: 6699883 (2004-03-01), Doeming et al.
patent: 7186716 (2007-03-01), Wei et al.
patent: 7361763 (2008-04-01), Arnold et al.
patent: 2002/0119982 (2002-08-01), Wang et al.
patent: 2004/0019052 (2004-01-01), Garland et al.
patent: 2006/0035898 (2006-02-01), Arnold et al.
patent: 2007/0043068 (2007-02-01), Arnold et al.
patent: 10053122 (2001-05-01), None
patent: 199559122 (2001-06-01), None
patent: WO-96-32391 (1996-10-01), None
patent: WO-00-24694 (2000-05-01), None
patent: WO-00-43393 (2000-07-01), None
patent: WO-00-71537 (2000-11-01), None
patent: WO-02-24694 (2002-03-01), None
patent: WO-02-051837 (2002-07-01), None
patent: WO-03-002563 (2003-01-01), None
patent: WO-03-024969 (2003-03-01), None
patent: WO-03-028724 (2003-04-01), None
patent: 03/045949 (2003-06-01), None
patent: WO-03-045949 (2003-06-01), None
patent: WO-03-068221 (2003-08-01), None
patent: WO-03-068773 (2003-08-01), None
patent: WO-03-082868 (2003-10-01), None
patent: WO-03-082869 (2003-10-01), None
patent: WO-03-087816 (2003-10-01), None
patent: WO-2004-014368 (2004-02-01), None
patent: WO-2004-024895 (2004-03-01), None
patent: WO-2004-032874 (2004-04-01), None
patent: WO-2004-078756 (2004-09-01), None
patent: WO-2004-078757 (2004-09-01), None
patent: WO-2004-101565 (2004-11-01), None
patent: WO-2004-101565 (2004-11-01), None
patent: WO-2005-028475 (2005-03-01), None
patent: WO-2005-062795 (2005-07-01), None
patent: WO-2005-085244 (2005-09-01), None
patent: WO-2005-095400 (2005-10-01), None
patent: WO-2006-124863 (2006-11-01), None
Milella et al., Reviews in clinical and experimental hematology, (Jun. 2003) vol. 7, No. 2, pp. 160-190.
Adamczyk, M. et al., “Synthesis of 3,7-dihydroimidazo[1,2a]pyrazine-3-ones and their chemiluminescent properties,” Tetrahedron 59:8129-8142 (2003).
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nuc. Acids Rec. 25(17):3389-3402 (1997).
Bach, T. et al., “Synthesis of 2′-Substituted 4-Bromo-2,4′-bithiazoles by Regioselective Cross-Coupling Reactions,” J. Org. Chem. 67:5789-5795 (2002).
Berge et al., “Pharmaceutical Salts,” J. Pharma. Sci. 66:1-19 (1977).
Blaney, J.M. and Dixon, J.S., “A good ligand is hard to find: Automated docking methods,” Perspectives in Drug Discovery and Design 1:301-319 (1993).
Bolm, C. et al., “Iron-Catalyzed Reactions in Organic Synthesis,” Chem. Rev. 104:6217-6254 (2004).
Boudier, A. et al., “New Applications of Polyfunctional Organometallic Compounds in Organic Synthesis,” Angew. Chem. Int. Ed. 39:4414-4435 (2000).
Brooks et al., “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations,” J. Comp. Chem. 4(2):187-217 (1983).
Charifson, P.S. et al., “Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins,” J. Med. Chem. 42:5100-5109 (1999).
Christman, U. and Villar, R., “Monoligated Palladium Species as Cataylists in Cross-Coupling Reactions,” Angew. Chem. 117:370-378 (2005).
Crabtree, S. and Cronan, J.E., “Facile and Gentle Method for Quantitative Lysis ofEscherichia coliandSalmonella typhimurium,” J. Bacteriol. 158(1):354-356 (1984).
Feldman et al., “Novel Small Molecule Inhibitors of 3-Phosphoinositide-Dependent Kinase-1 (PDK1),” JBC Papers In Press Published Mar. 16, 2005 as manuscript M501367200.
Fuerstner, A. et al., “Iron-Catalyzed Cross-Coupling Reactions,” J. Am. Chem. Soc. 124:13856-13863 (2002).
Goodsell and Olsen: “Automated Docking of Substrates to Proteins by Simulated Annealing,” Proteins: Structure, Function and Genetics 8:195-202 (1990).
Goulet et al., “ESPript: analysis of multiple sequence alignments in PostScript,” Bioinformatics 15(4):305-308 (1999).
Harrington et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,” Nature Medic ine Advance Online Publication Published online Feb. 22, 2004.
Hartwig, J.F., “Carbon-Heteroatom Bond-Forming Reductive Eliminations of Amines, Ethers, and Sulfides,” Acc. Chem. Res. 31:852-860 (1998).
Ishiyama, T. et al., “Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters,” J. Org. Chem. 60:7508-7510 (1995).
Ji, J. et al., “Selective Amination of Polyhalopyridines Catalyzed by a Palladium-Xanthphos Complex,” Org. Lett. 5:4611-4614 (2003).
Jones et al., “Molecular Recognition of Receptor Sites using a Genetic Algorithm with a Description of Desolvation,” J. Mol. Biol. 245:43-53 (1995).
Kuntz et al., “A Geometric Approach to Macromolecule-Ligand Interactions,” J. Mol. Biol. 161:269-288 (1982).
Ley, S. et al., “Modern Synthetic: Methods for Copper-Mediated C(Aryl)-O-, C(Aryl)-N- und C(Aryl)-S Bond Formation,” Angew. Chem. 115:5558-5607 (2003).
Littke, A.F., and Fu, G., “Palladium-Catalyzed Coupling Reactions of Aryl Chlorides,” Angew.Chem. 114:4177-4211 (2002).
Maryanoff, B.E. and Reitz, A.B., “The Wittig Olefination Reaction and Modifications Involving Phosphoryl-Stabilized Carbanions. Stereochemistry, Mechanism, and Selected Synthetic Aspects,” Chem. Rev. 89:863-927 (1989).
Matsui, T. et al., “Expression of Unphosphorylated Form of Human Double-Stranded RNA-Activated Protein Kinase inEscherichia coli,” Biochem. Biophys. Res. Commun. 284:798-807 (2001).
Meng et al., “Automated Docking with Grid-Based Energy Evaluation,” J. Comp. Chem. 13(4):505-524 (1992).
Mongin et al., “Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines, and carbolines). Part 1. Metallation of pyridines, quinolines anc carbolines,” Tetrahedron 57:4059-4090 (2001).
Nahm, S. and Weinreb, S.M., “N-Methoxy-N-Methylamides as Effective Acylating Agents,” Tetrahedron Lett. 22(39):3815-3818 (1981).
Navarro, O. et al., “Cross-Coupling and Dehalogenation Reactions Catalyzed by (N-Heterocyclic carbene)Pd(allyl)C1 Complexes,” J. Org. Chem. 69:3173-3180 (2004).
PCT/US08/65150 Search Report dated Aug. 21, 2008.
Rarey, M. et al., “A Fast Flexible Docking Method using an Incremental Construction Algorithm,” J. Mol. Biol. 261:470-489 (1996).
Sakamoto et al., “Condensed Heteroaromatic Ring Systems. XXII. Simple and General Synthesis of 1H-Pyrrolo-Pyridines,” Heterocycles 34(12):2379-2384 (1992).
Sapountzis, I. et al., “A New General Preparation of Polyfunctional Diarylamines by the Addition of Functionalized Arylmagnesium Compounds to Nitroarenes,” J. Am. Chem. Soc. 124:9390-9391 (2002).
Thompson et al., “DbClustal: rapid and reliable global multiple alignments of protein sequences detected by database searches,” Nucl. Acids Res. 28(15):2919-2926 (2000).
Travis, “Proteins and Organic Solvents Make an Eye-Opening Mix,” Science 262:1374 (1993).
Turck, A. et al., “Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 2. Metallation of pyrimidines, pyrazines, pyridazines and benzodiazines,” Tetrahedron 57:4489-4505 (2001).
Vilar, R., Christman,

Affiliated with

Also associated with

Rating

Fused ring heterocycle kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused ring heterocycle kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused ring heterocycle kinase modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4189196